基質(zhì)Gla蛋白(MGP)多克隆抗體
Polyclonal Antibody to Matrix Gla Protein (MGP)
MGLAP; GIG36; Cell growth-inhibiting gene 36 protein
- 編號PAB477Po01
- 物種Sus scrofa; Porcine (Pig，豬)相同的名稱，不同的物種。
- 來源多抗制備
- 宿主兔
- 效價-
- Ig類型IgG
- 純化方式抗原特異性親和純化
- 標(biāo)記物無標(biāo)記物
- 免疫原RPB477Po01-基質(zhì)Gla蛋白(MGP)重組蛋白
- 緩沖液成份磷酸鹽緩沖液（pH7.4,含有0.02% NaN3和50%甘油）
- 性狀液體
- 濃度0.5mg/mL
- 且適物種Mus musculus (Mouse，小鼠), Rattus norvegicus (Rat，大鼠)
- 應(yīng)用WB; IHC; ICC; IP.
如果抗體需用于流式細(xì)胞術(shù)，請參見流式抗體。 - 下載英文說明書 中文說明書
- 規(guī)格20μl100μl200μl1ml10ml
- 價格¥ 716¥ 1672¥ 2388¥ 5970¥ 23880
- 欲了解實際交易價格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
Figure. Western Blot; Sample: Recombinant MGP, Pig.
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對MGP的兔多克隆抗體。在免疫組織化學(xué)染色和免疫印跡實驗中能識別MGP。
用法
Western blotting: 0.01-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲，損失率低于5%。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Sus scrofa; Porcine (Pig，豬) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPB477Po01 | 基質(zhì)Gla蛋白(MGP)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAB477Po01 | 基質(zhì)Gla蛋白(MGP)多克隆抗體 | WB; IHC; ICC; IP. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Nephrology Dialysis Transplantation | Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells[PubMed: PMC3611891] |
| Maturitas. | Bone metabolism regulators and arterial stiffness in postmenopausal women[Pubmed: 23916080] |
| The Egyptian Rheumatologist | Osteoprotegerin (OPG) and Matrix Gla protein (MGP) in rheumatoid arthritis patients: Relation to disease activity[ScienceDirect: S1110116414000076] |
| Toxicology Reports | Canola and hydrogenated soybean oils accelerate ectopic bone formation induced by implantation of bone morphogenetic protein in mice[Researchgate:Source] |
| Lipids in Health and Disease | Markers of increased cardiovascular risk in patients with chronic kidney disease[Biomedcentral:Source] |
| Human & Veterinary Medicine | The behavior of circulating matrix Gla protein, matrix metalloproteinase-9 and nitrotyrosine in patients with varicose veins[Hvm:Source] |
| Pol Arch Med Wewn | Effect of Vitamin K2 on progression of atherosclerosis and vascular calcification in nondialyzed patients with chronic kidney disease stages 3-5[PubMed: 26176325] |
| Lipids Health Dis. | Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study[pmc:PMC4739105] |
| Kidney Blood Press Res. | Plasma Desphospho-Uncarboxylated Matrix Gla Protein as a Marker of Kidney Damage and Cardiovascular Risk in Advanced Stage of Chronic Kidney Disease[Pubmed:27100101] |
| Archives of?Oral?Biology | Matrix-Gla Protein rs4236 [A/G] gene polymorphism and serum and GCF levels of MGP in patients with subgingival dental calculus[pubmed:27348051] |
| Cell?Death?&?Disease | Mesenchymal stromal cells-derived matrix Gla protein contribute to the alleviation of experimental colitis[Pubmed:29880866] |
| Urology | High concentration of calcium promotes mineralization in NRK52E cells via inhibiting the expression of matrix Gla protein[Pubmed:29935264] |
| Clinica?Chimica?Acta | Serum total matrix Gla protein: Reference interval in healthy adults and variations in patients with vascular and osteoarticular diseases[Pubmed: 30597137] |
| Biological?Trace?Element?Research | Altered Mineral Metabolism and Disequilibrium Between Calcification Promoters and Inhibitors in Chronic Hemodialysis Patients[Pubmed: 30847765] |
| Renal Failure | Relationship of matrix Gla protein and vitamin K with vascular calcification in hemodialysis patients[Pubmed: 31538831] |
| Heliyon | Matrix Gla protein maintains normal and malignant hematopoietic progenitor cells by interacting with bone morphogenetic protein-4[Pubmed: 32322728] |